The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands
Aims: Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups. Met...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Clinical & Translational Endocrinology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623724000437 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850247146447568896 |
|---|---|
| author | Dide de Jongh Eline Bunnik Behiye Ozcan Robert Zietse Emma Massey |
| author_facet | Dide de Jongh Eline Bunnik Behiye Ozcan Robert Zietse Emma Massey |
| author_sort | Dide de Jongh |
| collection | DOAJ |
| description | Aims: Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups. Methods: Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework. Results: Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people. Conclusions: The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives. |
| format | Article |
| id | doaj-art-6514287fdb49489dbabd2ed5482a8f64 |
| institution | OA Journals |
| issn | 2214-6237 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical & Translational Endocrinology |
| spelling | doaj-art-6514287fdb49489dbabd2ed5482a8f642025-08-20T01:59:00ZengElsevierJournal of Clinical & Translational Endocrinology2214-62372024-12-013810037210.1016/j.jcte.2024.100372The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the NetherlandsDide de Jongh0Eline Bunnik1Behiye Ozcan2Robert Zietse3Emma Massey4Erasmus MC Transplant Institute, Department of Internal Medicine, University Medical Centre Rotterdam, 3000 CA Rotterdam, the Netherlands; Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC, University Medical Centre Rotterdam, 3000 CA Rotterdam, the Netherlands; Corresponding author at: Erasmus MC Transplant Institute, Department of Internal Medicine, University Medical Centre Rotterdam, 3000 CA Rotterdam, the Netherlands.Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC, University Medical Centre Rotterdam, 3000 CA Rotterdam, the NetherlandsDepartment of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, the NetherlandsDepartment of Medical Ethics, Philosophy and History of Medicine, Erasmus MC, University Medical Centre Rotterdam, 3000 CA Rotterdam, the NetherlandsErasmus MC Transplant Institute, Department of Internal Medicine, University Medical Centre Rotterdam, 3000 CA Rotterdam, the NetherlandsAims: Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups. Methods: Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework. Results: Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people. Conclusions: The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives.http://www.sciencedirect.com/science/article/pii/S2214623724000437Diabetes mellitus, Type 1Regenerative MedicineBioartificial organsPsychosocial FactorsEthicsQualitative research |
| spellingShingle | Dide de Jongh Eline Bunnik Behiye Ozcan Robert Zietse Emma Massey The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands Journal of Clinical & Translational Endocrinology Diabetes mellitus, Type 1 Regenerative Medicine Bioartificial organs Psychosocial Factors Ethics Qualitative research |
| title | The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands |
| title_full | The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands |
| title_fullStr | The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands |
| title_full_unstemmed | The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands |
| title_short | The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands |
| title_sort | bio artificial pancreas to treat type 1 diabetes perspectives from healthcare professionals in the netherlands |
| topic | Diabetes mellitus, Type 1 Regenerative Medicine Bioartificial organs Psychosocial Factors Ethics Qualitative research |
| url | http://www.sciencedirect.com/science/article/pii/S2214623724000437 |
| work_keys_str_mv | AT didedejongh thebioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT elinebunnik thebioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT behiyeozcan thebioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT robertzietse thebioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT emmamassey thebioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT didedejongh bioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT elinebunnik bioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT behiyeozcan bioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT robertzietse bioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands AT emmamassey bioartificialpancreastotreattype1diabetesperspectivesfromhealthcareprofessionalsinthenetherlands |